NCT01535157 2020-08-27
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
South Plains Oncology Consortium
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT00026091 2013-03-25
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098800 2010-03-24
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries
University of Arizona
Phase NA Completed